Analysis of The Cancer Research Atlas (TCGA) and the REMBRANDT databases indicated that PLOD2 can constitute an effective diagnostic marker to distinguish lower grade gliomas from GBM. This evidence concerns the gene PLOD2 and glioblastoma.